The Wire

Quick-hit updates from the worlds of medical marketing, including everything from clinical news to device approvals to agency expansion and consolidation.

Gilead, Tentarix collab to develop cancer, inflammatory disease therapies
Gilead, Tentarix collab to develop cancer, inflammatory disease therapies
Jack O'Brien
August 15, 2023
3:51 pm

Gilead has the option to acquire up to three selected Tentarix subsidiaries containing the programs developed through the partnership for $80 million per subsidiary.

Novartis spends $500M to acquire DtX Pharma, boost neuroscience capabilities
Novartis spends $500M to acquire DtX Pharma, boost neuroscience capabilities
Jack O'Brien
July 17, 2023
12:21 pm

The top asset Novartis is picking up through the deal is DtX Pharma’s Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) platform.

Eli Lilly to buy obesity drugmaker Versanis for nearly $2B
Eli Lilly to buy obesity drugmaker Versanis for nearly $2B
Jack O'Brien
July 14, 2023
1:13 pm

The Versanis acquisition marks yet another purchase for the dealmaking Lilly, which recently bought Sigilon Therapeutics for $34.6 million upfront and Dice Therapeutics for $2.4 billion.

Thermo Fisher Scientific set to acquire CorEvitas for $912M
Thermo Fisher Scientific set to acquire CorEvitas for $912M
Jack O'Brien
July 6, 2023
11:31 am

The CorEvitas deal is expected to be completed by the end of the year, Thermo Fisher stated, pending customary closing conditions and regulatory approvals.

Boundless Life Sciences teams with Fuse Health, forms new agency
Boundless Life Sciences teams with Fuse Health, forms new agency
Jack O'Brien
June 21, 2023
11:45 am

The two agencies are creating Boundless Medical Communications, which will focus on serving clients in the life sciences sector.

Eli Lilly scoops up Dice Therapeutics for $2.4B
Eli Lilly scoops up Dice Therapeutics for $2.4B
Jack O'Brien
June 20, 2023
10:54 am

The Dice deal has been approved by the boards of directors of both companies and is subject to customary closing conditions but is expected to close in Q3.

Astellas inks $1.9B strategic collab with Cullgen to progress protein degraders
Astellas inks $1.9B strategic collab with Cullgen to progress protein degraders
Jack O'Brien
June 15, 2023
10:11 am

The focal point of the development process for multiple targeted protein degraders is Cullgen’s uSMITE platform, which features novel E3 ligands.

Crosby lands $1.9M contract to promote Telehealth.HHS.gov
Crosby lands $1.9M contract to promote Telehealth.HHS.gov
Jack O'Brien
June 9, 2023
10:40 am

As part of this renewed effort, Crosby will establish an integrated marketing campaign to boost engagement, awareness and visits to Telehealth.HHS.gov.

Kate Therapeutics grants myotubular myopathy gene therapy to Astellas
Kate Therapeutics grants myotubular myopathy gene therapy to Astellas
Jack O'Brien
June 8, 2023
11:13 am

The Astellas license agreement was announced the same day that KateTx emerged from stealth mode with a $51 million Series A funding round.

Novo Nordisk enters talks to buy device maker Biocorp
Novo Nordisk enters talks to buy device maker Biocorp
Jack O'Brien
June 5, 2023
10:55 am

Novo is seeking to acquire a controlling stake in the company from majority shareholder Bio Jag for around $165 million.

  • From Our Partners